Use of AI in Genetic Diagnosis: Identifying Rare Diseases

By HEOR Staff Writer

May 17, 2024

Introduction

Every year, numerous children are born with severe genetic disorders, with a considerable number remaining undiagnosed due to the complexity of identifying causative genetic variants. The emergence of artificial intelligence (AI) in genetic diagnosis offers a promising avenue for addressing these challenges, pushing the boundaries of precision medicine.

Understanding the Diagnostic Challenge

Genetic disorders, often resulting from single-gene mutations, present a significant diagnostic challenge. Despite modern bioinformatics tools, the process of pinpointing the exact variant responsible for a disease remains a complex task, demanding both time and extensive knowledge. Despite the advent of sophisticated bioinformatics tools, the diagnostic rate for genetic disorders hovers between 30 and 40%.  This complexity underscores the need for more efficient diagnostic methodologies.

Figure 1. Schematic Diagram Illustrating the Reanalysis Process

The Power of AI in Genetic Analysis

AI systems, such as AI-MARRVEL (AIM), have been developed to enhance the diagnostic process for Mendelian disorders. These systems leverage patient clinical features and sequencing profiles, offering a sophisticated approach to variant prioritisation. AIM, in particular, is trained on a more than 3.5 million variant data points and curated by certified experts, embodying a significant leap forward in genetic diagnostics.

Navigating the Limitations of Current Tools

While AI systems like AIM mark a significant advancement, they are not without limitations. The inability to analyse certain types of genetic variations and a focus on coding variants restrict their scope. However, these challenges present opportunities for further innovation and integration of more comprehensive analytical tools.

The Future of Genetic Diagnosis

AI in genetic diagnosis is not just a theoretical concept but a practical tool with a web interface for real-world application. It has the potential to truly enhance the periodic reanalysis of undiagnosed cases, making it a feasible and cost-effective option for many. As AI continues to evolve, its integration into clinical practice promises to enhance patient outcomes and set a new norm in genetic medicine.

Reference url

Recent Posts

Long-Term HPV Vaccine Effectiveness: Sustained Protection Against Cervical Disease

By João L. Carapinha

March 19, 2026

HPV vaccine effectiveness is demonstrated in new clinical and real-world data from Merck, showcasing the sustained protection of GARDASIL®9 (9-valent Human Papillomavirus [HPV] vaccine) and GARDASIL® (4-valent HPV vaccine) against HPV-related cancers and diseases. Key findings include vaccine eff...
TAVI Reimbursement Expansion for Low- and Intermediate-Risk Patients: A New Era in Cardiovascular...
The TAVI reimbursement expansion announced by Zorginstituut Nederland on March 10, 2026, includes transcatheter aortic valve implantation (TAVI) in...
PRIME Scheme Evaluation: Insights from Enhanced Development Tools Pilot
The PRIME Scheme Evaluation of the European Medicines Agency’s (EMA) PRIority Medicines (PRIME), launched in 2016, confirms early and enhanced regulatory support accelerates medicines for unmet needs. A two-year pilot (April 2023–March 2025) tested three new features—regulatory roadmap and produc...